JPWO2022074124A5 - - Google Patents
Download PDFInfo
- Publication number
- JPWO2022074124A5 JPWO2022074124A5 JP2023521357A JP2023521357A JPWO2022074124A5 JP WO2022074124 A5 JPWO2022074124 A5 JP WO2022074124A5 JP 2023521357 A JP2023521357 A JP 2023521357A JP 2023521357 A JP2023521357 A JP 2023521357A JP WO2022074124 A5 JPWO2022074124 A5 JP WO2022074124A5
- Authority
- JP
- Japan
- Prior art keywords
- pharma
- cancer
- acceptable salt
- ceutically acceptable
- chemotherapeutic agent
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063089195P | 2020-10-08 | 2020-10-08 | |
| US63/089,195 | 2020-10-08 | ||
| PCT/EP2021/077703 WO2022074124A1 (en) | 2020-10-08 | 2021-10-07 | Combination therapy for treating cancer |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2023546362A JP2023546362A (ja) | 2023-11-02 |
| JPWO2022074124A5 true JPWO2022074124A5 (enExample) | 2024-09-20 |
| JP7818585B2 JP7818585B2 (ja) | 2026-02-20 |
Family
ID=78293953
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2023521357A Active JP7818585B2 (ja) | 2020-10-08 | 2021-10-07 | 癌を治療するための組み合わせ療法 |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20230372333A1 (enExample) |
| EP (1) | EP4225297B1 (enExample) |
| JP (1) | JP7818585B2 (enExample) |
| KR (1) | KR20230083291A (enExample) |
| CN (1) | CN116194110B (enExample) |
| AU (1) | AU2021356123B2 (enExample) |
| BR (1) | BR112023005160A2 (enExample) |
| CA (1) | CA3197056A1 (enExample) |
| DK (1) | DK4225297T3 (enExample) |
| ES (1) | ES3005507T3 (enExample) |
| FI (1) | FI4225297T3 (enExample) |
| HU (1) | HUE069249T2 (enExample) |
| IL (1) | IL301687A (enExample) |
| MX (1) | MX2023004156A (enExample) |
| PL (1) | PL4225297T3 (enExample) |
| PT (1) | PT4225297T (enExample) |
| TW (1) | TW202228693A (enExample) |
| WO (1) | WO2022074124A1 (enExample) |
| ZA (1) | ZA202304965B (enExample) |
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2022222995A1 (zh) * | 2021-04-23 | 2022-10-27 | 南京明德新药研发有限公司 | 吡啶酰胺类化合物 |
| CN118119618A (zh) * | 2021-09-09 | 2024-05-31 | 南京奥利墨斯医药科技有限公司 | 一种杂芳环类化合物及其应用 |
| US20230250428A1 (en) * | 2022-02-07 | 2023-08-10 | Alliance Of Cardiovascular Researchers | Method and composition for early detection of malignancies |
| IL316016A (en) * | 2022-04-07 | 2024-11-01 | Astrazeneca Ab | Combined treatment for cancer |
| IL316019A (en) * | 2022-04-07 | 2024-11-01 | Astrazeneca Ab | Combined treatment for cancer |
| WO2025011494A1 (zh) * | 2023-07-07 | 2025-01-16 | 优领医药科技(香港)有限公司 | 含哌嗪并环类衍生物的晶型、其盐型、其制备方法及应用 |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US10238630B2 (en) * | 2014-05-28 | 2019-03-26 | Eisai R&D Management Co., Ltd. | Use of eribulin and poly (ADP ribose) polymerase (PARP) inhibitors as combination therapy for the treatment of cancer |
| TWI837403B (zh) * | 2019-07-19 | 2024-04-01 | 瑞典商阿斯特捷利康公司 | 化學化合物 |
-
2021
- 2021-10-06 TW TW110137116A patent/TW202228693A/zh unknown
- 2021-10-07 IL IL301687A patent/IL301687A/en unknown
- 2021-10-07 MX MX2023004156A patent/MX2023004156A/es unknown
- 2021-10-07 EP EP21794474.3A patent/EP4225297B1/en active Active
- 2021-10-07 WO PCT/EP2021/077703 patent/WO2022074124A1/en not_active Ceased
- 2021-10-07 PL PL21794474.3T patent/PL4225297T3/pl unknown
- 2021-10-07 AU AU2021356123A patent/AU2021356123B2/en active Active
- 2021-10-07 ES ES21794474T patent/ES3005507T3/es active Active
- 2021-10-07 US US18/248,108 patent/US20230372333A1/en active Pending
- 2021-10-07 PT PT217944743T patent/PT4225297T/pt unknown
- 2021-10-07 HU HUE21794474A patent/HUE069249T2/hu unknown
- 2021-10-07 CA CA3197056A patent/CA3197056A1/en active Pending
- 2021-10-07 BR BR112023005160A patent/BR112023005160A2/pt unknown
- 2021-10-07 JP JP2023521357A patent/JP7818585B2/ja active Active
- 2021-10-07 FI FIEP21794474.3T patent/FI4225297T3/fi active
- 2021-10-07 DK DK21794474.3T patent/DK4225297T3/da active
- 2021-10-07 KR KR1020237013320A patent/KR20230083291A/ko active Pending
- 2021-10-07 CN CN202180065599.5A patent/CN116194110B/zh active Active
-
2023
- 2023-05-04 ZA ZA2023/04965A patent/ZA202304965B/en unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR101673731B1 (ko) | 벰루페닙 및 mdm2 억제제의, 증식성 질환 치료용 복합 요법 | |
| FI4225297T3 (fi) | Yhdistelmälääkehoito syövän hoidossa | |
| JP2012515184A (ja) | 大腸がんの治療方法 | |
| CN108135901A (zh) | 胆管癌的治疗 | |
| TWI522105B (zh) | 偏亞砷酸鈉於治療癌疼痛及炎症之用途 | |
| JP2003533485A5 (enExample) | ||
| CN103533940A (zh) | 治疗晚期实体瘤的方法 | |
| JP2001513110A (ja) | 腫瘍治療方法 | |
| CN104800858A (zh) | Hsp90抑制肽偶联物及其在肿瘤治疗中的应用 | |
| JPWO2022074124A5 (enExample) | ||
| CN110522753A (zh) | 一种新型抗肿瘤药物组合物、制剂和应用 | |
| TW202539651A (zh) | 化合物在製備治療非髓系惡性腫瘤患者的貧血藥物中的應用 | |
| AU2018348892B2 (en) | Formulation containing A-decarbonized-5a androstane compound for increasing white blood cell and use thereof | |
| JP2022542725A (ja) | 化合物又はその薬学的に許容される塩、二量体又は三量体のがん治療用医薬品の調製における応用 | |
| US10441564B2 (en) | Fructose analogs and their combinations as anti-cancer agents | |
| CN118717798A (zh) | 一种提高肿瘤化疗效果的药物及氢分子在制备用于提高肿瘤化疗效果药物中的应用 | |
| JP6549107B2 (ja) | がんの処置のための、ｒｏ５５０３７８１、カペシタビン及びオキサリプラチンの組み合わせ | |
| JP2007508331A (ja) | オキソプラチン、その塩および誘導体を含む医薬組成物 | |
| CN121102377B (zh) | 含首荟通便胶囊的用于治疗结直肠癌的药物组合物及其应用 | |
| TWI912688B (zh) | 用於治療三陰性乳癌之藥物組合物 | |
| RU2773153C1 (ru) | Способ повышения уровня гемоглобина в крови у пациента, больного раком | |
| Cherchenko et al. | INTRA-ARTERIAL CHEMOTHERAPY IN ADVANCED PANCREATIC CANCER: A LITERATURE REVIEW | |
| KR20260014535A (ko) | 종양 질환의 치료에서 약물 접합체의 용도 및 그 방법 | |
| CN106176757B (zh) | 一种化合物与替吉奥联合在制备治疗增生性疾病中的药物中的用途 | |
| WO2025209442A1 (zh) | 偶联物在治疗肿瘤疾病中的用途及方法 |